COMP <GO>
PRGO vs LKFT // EV/EBITDA & P/E VALUATION
Perrigo Company plc (NYSE) VS. Lakefront Biotherapeutics (NASDAQ) • 15-METRIC TALLY: PRGO 2
— LKFT 1
■ METRIC PARITY
LAST: $15.78 (-0.75%) • MKT CAP: $2.19B
valuation
—
LAST: $32.28 (-0.15%) • MKT CAP: $2.13B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRGO VS. LKFT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRGO | LKFT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.60% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.58% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -26.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -33.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -2.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 7.22% | 0.00% | +7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.8 | 69.3 | -14.50 | LKFT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.19B | $2.13B | $62.6M | PRGO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRGO REV | LKFT REV | PRGO GROSS % | LKFT GROSS % | PRGO FCF | LKFT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.25B | — | 35.1% | — | $145.1M | — |
| FY 2024 | $4.37B | — | 35.3% | — | $244.6M | — |
| FY 2023 | $4.66B | — | — | — | $405.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRGO // BETA —
LKFT // BETA —